Global Anti-Neprilysin Market

Anti-Neprilysin Comprehensive Study by Type (TD-0714, STR-324, PL-265, LHW-090, Others), Application (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer's Disease, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), End-Use (Hospitals, Specialty Centers, Others) Players and Region - Global Market Outlook to 2026

Anti-Neprilysin Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Anti-Neprilysin Market Scope?
Neprilysin inhibitors hereby cause an increase in natriuretic peptides, which are mainly important for maintaining fluid as well as sodium balance through natriuresis, diuresis, and vasodilation. This lowers blood pressure and effectively treats heart failure. Neprilysin can be used in combination with other medications to improve treatment for heart failure. Therefore, anti-neprilysin drugs are used to treat high blood pressure, heart failure, kidney disease, and others. Sacubitril / Valsartan is used instead of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) and in conjunction with treatment when it does not work in patients with heart disease. The inhibition of neprilysin helps increase the level of natriuretic peptides. Neprilysin inhibitors help lower the risk of heart failure and lower blood pressure. The COVID-19 pandemic has significantly increased the demand for several drugs. The spread of coronavirus is also having a negative impact on sales for companies whose product demand is heavily reliant on selective disease treatments.

The Anti-Neprilysin market study is being classified by Type (TD-0714, STR-324, PL-265, LHW-090 and Others), by Application (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer's Disease and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.

Bioprojet SCR (France), Novartis AG (Switzerland), Pharmaleads SA (France), Theravance Biopharma Inc. (United States), Cipla Limited (India) and Oceanic Pharmachem Pvt. Ltd. (India) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Anti-Neprilysin market by Type, Application and Region.

On the basis of geography, the market of Anti-Neprilysin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
On 02 March 2020, Otsuka Pharmaceutical Co., Ltd and Novartis Pharma execute an agreement for Novartis Pharma angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 treatment for Chronic heart failure. As per the agreement, Novartis Pharma and Otsuka will work together to promote LCZ696 to healthcare professionals. Novartis Pharma will receive a JPY 10 billion upfront payment from Otsuka, as well as subsequent milestone payments. Novartis Pharma will pay Otsuka a promotion fee based on the product's sales. LCZ696 is a novel medication that decreases cardiac load in patients with chronic heart failure by activating a protective neurohormonal mechanism while reducing the detrimental effects of renin-angiotensin-aldosterone system overactivity (RAAS).
On 24 June 2020, Novartis announces USFDA accepted the supplemental new drug application of Entresto that contains an Anti-Neprilysin inhibitor inpatient with HFpEF and HFrEF for both chronic heart failure. Entresto is a prescription drug that helps people with long-term (chronic) heart failure minimize their risk of cardiovascular death and heart failure hospitalization (HFrEF). Entresto comprises sacubitril, a neprilysin inhibitor, and valsartan, an ARB. Entresto is a twice-daily prescription drug that works by increasing the positive neurohormonal systems while decreasing the negative effects of an overactive renin-angiotensin-aldosterone system.
The US Food and Drug Administration (FDA) had thereby approved Entresto (sacubitril/valsartan) for the purpose of treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction in pediatric patients that are 1 year of age and older. Entresto reduces NT-proBNP and is believed to improve cardiovascular outcomes.

Influencing Market Trend
  • Growing Awareness Regarding Neprilysin
  • The Increasing Number of Clinical Trials of Anti-Neprilysin Drugs
  • Favorable Reimbursement Policies
  • Rising Trend in Consumption of Foods High In Sodium, Cholesterol, and Fats; and Smoking of Tobacco

Market Drivers
  • The Increasing Prevalence of the Congestive Heart Failure All Over the Globe
  • Rising Prevalence of Hypertension
  • Lack of Enough Physical Activity
  • The Growing Patient Pool and Increasing Technological Advancements
  • Increasing Geriatric Population, And the Constantly Changing Lifestyle Habits

Opportunities
  • Rising Healthcare Expenditure
  • Increasing Initiatives Regarding Health Care by Governments

Restraints
  • A Strong Pipeline and Product Approvals

Challenges
  • Serious Side-Effects of Such Drugs


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Venture Capitalists, Government Regulatory, Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • TD-0714
  • STR-324
  • PL-265
  • LHW-090
  • Others
By Application
  • Acute Heart Failure
  • Cancer Pain
  • Hypertension
  • Alzheimer's Disease
  • Others
By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End-Use
  • Hospitals
  • Specialty Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Prevalence of the Congestive Heart Failure All Over the Globe
      • 3.2.2. Rising Prevalence of Hypertension
      • 3.2.3. Lack of Enough Physical Activity
      • 3.2.4. The Growing Patient Pool and Increasing Technological Advancements
      • 3.2.5. Increasing Geriatric Population, And the Constantly Changing Lifestyle Habits
    • 3.3. Market Challenges
      • 3.3.1. Serious Side-Effects of Such Drugs
    • 3.4. Market Trends
      • 3.4.1. Growing Awareness Regarding Neprilysin
      • 3.4.2. The Increasing Number of Clinical Trials of Anti-Neprilysin Drugs
      • 3.4.3. Favorable Reimbursement Policies
      • 3.4.4. Rising Trend in Consumption of Foods High In Sodium, Cholesterol, and Fats; and Smoking of Tobacco
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-Neprilysin, by Type, Application, Distribution Channel, End-Use and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Anti-Neprilysin (Value)
      • 5.2.1. Global Anti-Neprilysin by: Type (Value)
        • 5.2.1.1. TD-0714
        • 5.2.1.2. STR-324
        • 5.2.1.3. PL-265
        • 5.2.1.4. LHW-090
        • 5.2.1.5. Others
      • 5.2.2. Global Anti-Neprilysin by: Application (Value)
        • 5.2.2.1. Acute Heart Failure
        • 5.2.2.2. Cancer Pain
        • 5.2.2.3. Hypertension
        • 5.2.2.4. Alzheimer's Disease
        • 5.2.2.5. Others
      • 5.2.3. Global Anti-Neprilysin by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Anti-Neprilysin by: End-Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Specialty Centers
        • 5.2.4.3. Others
      • 5.2.5. Global Anti-Neprilysin Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Anti-Neprilysin (Volume)
      • 5.3.1. Global Anti-Neprilysin by: Type (Volume)
        • 5.3.1.1. TD-0714
        • 5.3.1.2. STR-324
        • 5.3.1.3. PL-265
        • 5.3.1.4. LHW-090
        • 5.3.1.5. Others
      • 5.3.2. Global Anti-Neprilysin by: Application (Volume)
        • 5.3.2.1. Acute Heart Failure
        • 5.3.2.2. Cancer Pain
        • 5.3.2.3. Hypertension
        • 5.3.2.4. Alzheimer's Disease
        • 5.3.2.5. Others
      • 5.3.3. Global Anti-Neprilysin by: Distribution Channel (Volume)
        • 5.3.3.1. Hospitals Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Anti-Neprilysin by: End-Use (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Specialty Centers
        • 5.3.4.3. Others
      • 5.3.5. Global Anti-Neprilysin Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Anti-Neprilysin (Price)
      • 5.4.1. Global Anti-Neprilysin by: Type (Price)
  • 6. Anti-Neprilysin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bioprojet SCR (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pharmaleads SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Theravance Biopharma Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cipla Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Oceanic Pharmachem Pvt. Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Anti-Neprilysin Sale, by Type, Application, Distribution Channel, End-Use and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Anti-Neprilysin (Value)
      • 7.2.1. Global Anti-Neprilysin by: Type (Value)
        • 7.2.1.1. TD-0714
        • 7.2.1.2. STR-324
        • 7.2.1.3. PL-265
        • 7.2.1.4. LHW-090
        • 7.2.1.5. Others
      • 7.2.2. Global Anti-Neprilysin by: Application (Value)
        • 7.2.2.1. Acute Heart Failure
        • 7.2.2.2. Cancer Pain
        • 7.2.2.3. Hypertension
        • 7.2.2.4. Alzheimer's Disease
        • 7.2.2.5. Others
      • 7.2.3. Global Anti-Neprilysin by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Anti-Neprilysin by: End-Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Specialty Centers
        • 7.2.4.3. Others
      • 7.2.5. Global Anti-Neprilysin Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Anti-Neprilysin (Volume)
      • 7.3.1. Global Anti-Neprilysin by: Type (Volume)
        • 7.3.1.1. TD-0714
        • 7.3.1.2. STR-324
        • 7.3.1.3. PL-265
        • 7.3.1.4. LHW-090
        • 7.3.1.5. Others
      • 7.3.2. Global Anti-Neprilysin by: Application (Volume)
        • 7.3.2.1. Acute Heart Failure
        • 7.3.2.2. Cancer Pain
        • 7.3.2.3. Hypertension
        • 7.3.2.4. Alzheimer's Disease
        • 7.3.2.5. Others
      • 7.3.3. Global Anti-Neprilysin by: Distribution Channel (Volume)
        • 7.3.3.1. Hospitals Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Anti-Neprilysin by: End-Use (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Specialty Centers
        • 7.3.4.3. Others
      • 7.3.5. Global Anti-Neprilysin Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Anti-Neprilysin (Price)
      • 7.4.1. Global Anti-Neprilysin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-Neprilysin: by Type(USD Million)
  • Table 2. Anti-Neprilysin TD-0714 , by Region USD Million (2015-2020)
  • Table 3. Anti-Neprilysin STR-324 , by Region USD Million (2015-2020)
  • Table 4. Anti-Neprilysin PL-265 , by Region USD Million (2015-2020)
  • Table 5. Anti-Neprilysin LHW-090 , by Region USD Million (2015-2020)
  • Table 6. Anti-Neprilysin Others , by Region USD Million (2015-2020)
  • Table 7. Anti-Neprilysin: by Application(USD Million)
  • Table 8. Anti-Neprilysin Acute Heart Failure , by Region USD Million (2015-2020)
  • Table 9. Anti-Neprilysin Cancer Pain , by Region USD Million (2015-2020)
  • Table 10. Anti-Neprilysin Hypertension , by Region USD Million (2015-2020)
  • Table 11. Anti-Neprilysin Alzheimer's Disease , by Region USD Million (2015-2020)
  • Table 12. Anti-Neprilysin Others , by Region USD Million (2015-2020)
  • Table 13. Anti-Neprilysin: by Distribution Channel(USD Million)
  • Table 14. Anti-Neprilysin Hospitals Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Anti-Neprilysin Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Anti-Neprilysin Online Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Anti-Neprilysin: by End-Use(USD Million)
  • Table 18. Anti-Neprilysin Hospitals , by Region USD Million (2015-2020)
  • Table 19. Anti-Neprilysin Specialty Centers , by Region USD Million (2015-2020)
  • Table 20. Anti-Neprilysin Others , by Region USD Million (2015-2020)
  • Table 21. South America Anti-Neprilysin, by Country USD Million (2015-2020)
  • Table 22. South America Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 23. South America Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 24. South America Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 25. South America Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 26. Brazil Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 27. Brazil Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 28. Brazil Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 29. Brazil Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 30. Argentina Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 31. Argentina Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 32. Argentina Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 33. Argentina Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 34. Rest of South America Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 37. Rest of South America Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 38. Asia Pacific Anti-Neprilysin, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 42. Asia Pacific Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 43. China Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 44. China Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 45. China Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 46. China Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 47. Japan Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 48. Japan Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 49. Japan Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 50. Japan Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 51. India Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 52. India Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 53. India Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 54. India Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 55. South Korea Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 56. South Korea Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 57. South Korea Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 58. South Korea Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 59. Taiwan Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 60. Taiwan Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 61. Taiwan Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 62. Taiwan Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 63. Australia Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 64. Australia Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 65. Australia Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 66. Australia Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 71. Europe Anti-Neprilysin, by Country USD Million (2015-2020)
  • Table 72. Europe Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 73. Europe Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 74. Europe Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 75. Europe Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 76. Germany Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 77. Germany Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 78. Germany Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 79. Germany Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 80. France Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 81. France Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 82. France Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 83. France Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 84. Italy Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 85. Italy Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 86. Italy Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 87. Italy Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 88. United Kingdom Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 90. United Kingdom Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 91. United Kingdom Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 92. Netherlands Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 93. Netherlands Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 94. Netherlands Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 95. Netherlands Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 96. Rest of Europe Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 98. Rest of Europe Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 99. Rest of Europe Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 100. MEA Anti-Neprilysin, by Country USD Million (2015-2020)
  • Table 101. MEA Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 102. MEA Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 103. MEA Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 104. MEA Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 105. Middle East Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 106. Middle East Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 107. Middle East Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 108. Middle East Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 109. Africa Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 110. Africa Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 111. Africa Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 112. Africa Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 113. North America Anti-Neprilysin, by Country USD Million (2015-2020)
  • Table 114. North America Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 115. North America Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 116. North America Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 117. North America Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 118. United States Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 119. United States Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 120. United States Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 121. United States Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 122. Canada Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 123. Canada Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 124. Canada Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 125. Canada Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 126. Mexico Anti-Neprilysin, by Type USD Million (2015-2020)
  • Table 127. Mexico Anti-Neprilysin, by Application USD Million (2015-2020)
  • Table 128. Mexico Anti-Neprilysin, by Distribution Channel USD Million (2015-2020)
  • Table 129. Mexico Anti-Neprilysin, by End-Use USD Million (2015-2020)
  • Table 130. Anti-Neprilysin Sales: by Type(K Tons)
  • Table 131. Anti-Neprilysin Sales TD-0714 , by Region K Tons (2015-2020)
  • Table 132. Anti-Neprilysin Sales STR-324 , by Region K Tons (2015-2020)
  • Table 133. Anti-Neprilysin Sales PL-265 , by Region K Tons (2015-2020)
  • Table 134. Anti-Neprilysin Sales LHW-090 , by Region K Tons (2015-2020)
  • Table 135. Anti-Neprilysin Sales Others , by Region K Tons (2015-2020)
  • Table 136. Anti-Neprilysin Sales: by Application(K Tons)
  • Table 137. Anti-Neprilysin Sales Acute Heart Failure , by Region K Tons (2015-2020)
  • Table 138. Anti-Neprilysin Sales Cancer Pain , by Region K Tons (2015-2020)
  • Table 139. Anti-Neprilysin Sales Hypertension , by Region K Tons (2015-2020)
  • Table 140. Anti-Neprilysin Sales Alzheimer's Disease , by Region K Tons (2015-2020)
  • Table 141. Anti-Neprilysin Sales Others , by Region K Tons (2015-2020)
  • Table 142. Anti-Neprilysin Sales: by Distribution Channel(K Tons)
  • Table 143. Anti-Neprilysin Sales Hospitals Pharmacies , by Region K Tons (2015-2020)
  • Table 144. Anti-Neprilysin Sales Retail Pharmacies , by Region K Tons (2015-2020)
  • Table 145. Anti-Neprilysin Sales Online Pharmacies , by Region K Tons (2015-2020)
  • Table 146. Anti-Neprilysin Sales: by End-Use(K Tons)
  • Table 147. Anti-Neprilysin Sales Hospitals , by Region K Tons (2015-2020)
  • Table 148. Anti-Neprilysin Sales Specialty Centers , by Region K Tons (2015-2020)
  • Table 149. Anti-Neprilysin Sales Others , by Region K Tons (2015-2020)
  • Table 150. South America Anti-Neprilysin Sales, by Country K Tons (2015-2020)
  • Table 151. South America Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 152. South America Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 153. South America Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 154. South America Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 155. Brazil Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 156. Brazil Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 157. Brazil Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 158. Brazil Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 159. Argentina Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 160. Argentina Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 161. Argentina Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 162. Argentina Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 163. Rest of South America Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 164. Rest of South America Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 165. Rest of South America Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 166. Rest of South America Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 167. Asia Pacific Anti-Neprilysin Sales, by Country K Tons (2015-2020)
  • Table 168. Asia Pacific Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 169. Asia Pacific Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 170. Asia Pacific Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 171. Asia Pacific Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 172. China Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 173. China Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 174. China Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 175. China Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 176. Japan Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 177. Japan Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 178. Japan Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 179. Japan Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 180. India Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 181. India Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 182. India Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 183. India Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 184. South Korea Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 185. South Korea Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 186. South Korea Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 187. South Korea Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 188. Taiwan Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 189. Taiwan Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 190. Taiwan Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 191. Taiwan Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 192. Australia Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 193. Australia Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 194. Australia Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 195. Australia Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 196. Rest of Asia-Pacific Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 197. Rest of Asia-Pacific Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 198. Rest of Asia-Pacific Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 199. Rest of Asia-Pacific Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 200. Europe Anti-Neprilysin Sales, by Country K Tons (2015-2020)
  • Table 201. Europe Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 202. Europe Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 203. Europe Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 204. Europe Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 205. Germany Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 206. Germany Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 207. Germany Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 208. Germany Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 209. France Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 210. France Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 211. France Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 212. France Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 213. Italy Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 214. Italy Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 215. Italy Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 216. Italy Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 217. United Kingdom Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 218. United Kingdom Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 219. United Kingdom Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 220. United Kingdom Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 221. Netherlands Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 222. Netherlands Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 223. Netherlands Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 224. Netherlands Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 225. Rest of Europe Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 226. Rest of Europe Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 227. Rest of Europe Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 228. Rest of Europe Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 229. MEA Anti-Neprilysin Sales, by Country K Tons (2015-2020)
  • Table 230. MEA Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 231. MEA Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 232. MEA Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 233. MEA Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 234. Middle East Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 235. Middle East Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 236. Middle East Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 237. Middle East Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 238. Africa Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 239. Africa Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 240. Africa Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 241. Africa Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 242. North America Anti-Neprilysin Sales, by Country K Tons (2015-2020)
  • Table 243. North America Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 244. North America Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 245. North America Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 246. North America Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 247. United States Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 248. United States Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 249. United States Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 250. United States Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 251. Canada Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 252. Canada Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 253. Canada Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 254. Canada Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 255. Mexico Anti-Neprilysin Sales, by Type K Tons (2015-2020)
  • Table 256. Mexico Anti-Neprilysin Sales, by Application K Tons (2015-2020)
  • Table 257. Mexico Anti-Neprilysin Sales, by Distribution Channel K Tons (2015-2020)
  • Table 258. Mexico Anti-Neprilysin Sales, by End-Use K Tons (2015-2020)
  • Table 259. Anti-Neprilysin: by Type(USD/Units)
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Anti-Neprilysin: by Type(USD Million)
  • Table 267. Anti-Neprilysin TD-0714 , by Region USD Million (2021-2026)
  • Table 268. Anti-Neprilysin STR-324 , by Region USD Million (2021-2026)
  • Table 269. Anti-Neprilysin PL-265 , by Region USD Million (2021-2026)
  • Table 270. Anti-Neprilysin LHW-090 , by Region USD Million (2021-2026)
  • Table 271. Anti-Neprilysin Others , by Region USD Million (2021-2026)
  • Table 272. Anti-Neprilysin: by Application(USD Million)
  • Table 273. Anti-Neprilysin Acute Heart Failure , by Region USD Million (2021-2026)
  • Table 274. Anti-Neprilysin Cancer Pain , by Region USD Million (2021-2026)
  • Table 275. Anti-Neprilysin Hypertension , by Region USD Million (2021-2026)
  • Table 276. Anti-Neprilysin Alzheimer's Disease , by Region USD Million (2021-2026)
  • Table 277. Anti-Neprilysin Others , by Region USD Million (2021-2026)
  • Table 278. Anti-Neprilysin: by Distribution Channel(USD Million)
  • Table 279. Anti-Neprilysin Hospitals Pharmacies , by Region USD Million (2021-2026)
  • Table 280. Anti-Neprilysin Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 281. Anti-Neprilysin Online Pharmacies , by Region USD Million (2021-2026)
  • Table 282. Anti-Neprilysin: by End-Use(USD Million)
  • Table 283. Anti-Neprilysin Hospitals , by Region USD Million (2021-2026)
  • Table 284. Anti-Neprilysin Specialty Centers , by Region USD Million (2021-2026)
  • Table 285. Anti-Neprilysin Others , by Region USD Million (2021-2026)
  • Table 286. South America Anti-Neprilysin, by Country USD Million (2021-2026)
  • Table 287. South America Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 288. South America Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 289. South America Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 290. South America Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 291. Brazil Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 292. Brazil Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 293. Brazil Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 294. Brazil Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 295. Argentina Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 296. Argentina Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 297. Argentina Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 298. Argentina Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 299. Rest of South America Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 300. Rest of South America Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 301. Rest of South America Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 302. Rest of South America Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 303. Asia Pacific Anti-Neprilysin, by Country USD Million (2021-2026)
  • Table 304. Asia Pacific Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 305. Asia Pacific Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 306. Asia Pacific Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 307. Asia Pacific Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 308. China Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 309. China Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 310. China Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 311. China Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 312. Japan Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 313. Japan Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 314. Japan Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 315. Japan Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 316. India Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 317. India Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 318. India Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 319. India Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 320. South Korea Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 321. South Korea Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 322. South Korea Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 323. South Korea Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 324. Taiwan Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 325. Taiwan Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 326. Taiwan Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 327. Taiwan Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 328. Australia Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 329. Australia Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 330. Australia Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 331. Australia Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 332. Rest of Asia-Pacific Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 333. Rest of Asia-Pacific Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 334. Rest of Asia-Pacific Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 335. Rest of Asia-Pacific Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 336. Europe Anti-Neprilysin, by Country USD Million (2021-2026)
  • Table 337. Europe Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 338. Europe Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 339. Europe Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 340. Europe Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 341. Germany Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 342. Germany Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 343. Germany Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 344. Germany Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 345. France Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 346. France Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 347. France Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 348. France Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 349. Italy Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 350. Italy Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 351. Italy Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 352. Italy Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 353. United Kingdom Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 354. United Kingdom Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 355. United Kingdom Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 356. United Kingdom Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 357. Netherlands Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 358. Netherlands Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 359. Netherlands Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 360. Netherlands Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 361. Rest of Europe Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 362. Rest of Europe Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 363. Rest of Europe Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 364. Rest of Europe Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 365. MEA Anti-Neprilysin, by Country USD Million (2021-2026)
  • Table 366. MEA Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 367. MEA Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 368. MEA Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 369. MEA Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 370. Middle East Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 371. Middle East Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 372. Middle East Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 373. Middle East Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 374. Africa Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 375. Africa Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 376. Africa Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 377. Africa Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 378. North America Anti-Neprilysin, by Country USD Million (2021-2026)
  • Table 379. North America Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 380. North America Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 381. North America Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 382. North America Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 383. United States Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 384. United States Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 385. United States Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 386. United States Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 387. Canada Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 388. Canada Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 389. Canada Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 390. Canada Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 391. Mexico Anti-Neprilysin, by Type USD Million (2021-2026)
  • Table 392. Mexico Anti-Neprilysin, by Application USD Million (2021-2026)
  • Table 393. Mexico Anti-Neprilysin, by Distribution Channel USD Million (2021-2026)
  • Table 394. Mexico Anti-Neprilysin, by End-Use USD Million (2021-2026)
  • Table 395. Anti-Neprilysin Sales: by Type(K Tons)
  • Table 396. Anti-Neprilysin Sales TD-0714 , by Region K Tons (2021-2026)
  • Table 397. Anti-Neprilysin Sales STR-324 , by Region K Tons (2021-2026)
  • Table 398. Anti-Neprilysin Sales PL-265 , by Region K Tons (2021-2026)
  • Table 399. Anti-Neprilysin Sales LHW-090 , by Region K Tons (2021-2026)
  • Table 400. Anti-Neprilysin Sales Others , by Region K Tons (2021-2026)
  • Table 401. Anti-Neprilysin Sales: by Application(K Tons)
  • Table 402. Anti-Neprilysin Sales Acute Heart Failure , by Region K Tons (2021-2026)
  • Table 403. Anti-Neprilysin Sales Cancer Pain , by Region K Tons (2021-2026)
  • Table 404. Anti-Neprilysin Sales Hypertension , by Region K Tons (2021-2026)
  • Table 405. Anti-Neprilysin Sales Alzheimer's Disease , by Region K Tons (2021-2026)
  • Table 406. Anti-Neprilysin Sales Others , by Region K Tons (2021-2026)
  • Table 407. Anti-Neprilysin Sales: by Distribution Channel(K Tons)
  • Table 408. Anti-Neprilysin Sales Hospitals Pharmacies , by Region K Tons (2021-2026)
  • Table 409. Anti-Neprilysin Sales Retail Pharmacies , by Region K Tons (2021-2026)
  • Table 410. Anti-Neprilysin Sales Online Pharmacies , by Region K Tons (2021-2026)
  • Table 411. Anti-Neprilysin Sales: by End-Use(K Tons)
  • Table 412. Anti-Neprilysin Sales Hospitals , by Region K Tons (2021-2026)
  • Table 413. Anti-Neprilysin Sales Specialty Centers , by Region K Tons (2021-2026)
  • Table 414. Anti-Neprilysin Sales Others , by Region K Tons (2021-2026)
  • Table 415. South America Anti-Neprilysin Sales, by Country K Tons (2021-2026)
  • Table 416. South America Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 417. South America Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 418. South America Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 419. South America Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 420. Brazil Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 421. Brazil Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 422. Brazil Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 423. Brazil Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 424. Argentina Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 425. Argentina Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 426. Argentina Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 427. Argentina Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 428. Rest of South America Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 429. Rest of South America Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 430. Rest of South America Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 431. Rest of South America Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 432. Asia Pacific Anti-Neprilysin Sales, by Country K Tons (2021-2026)
  • Table 433. Asia Pacific Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 434. Asia Pacific Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 435. Asia Pacific Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 436. Asia Pacific Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 437. China Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 438. China Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 439. China Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 440. China Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 441. Japan Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 442. Japan Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 443. Japan Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 444. Japan Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 445. India Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 446. India Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 447. India Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 448. India Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 449. South Korea Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 450. South Korea Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 451. South Korea Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 452. South Korea Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 453. Taiwan Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 454. Taiwan Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 455. Taiwan Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 456. Taiwan Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 457. Australia Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 458. Australia Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 459. Australia Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 460. Australia Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 461. Rest of Asia-Pacific Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 462. Rest of Asia-Pacific Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 463. Rest of Asia-Pacific Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 464. Rest of Asia-Pacific Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 465. Europe Anti-Neprilysin Sales, by Country K Tons (2021-2026)
  • Table 466. Europe Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 467. Europe Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 468. Europe Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 469. Europe Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 470. Germany Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 471. Germany Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 472. Germany Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 473. Germany Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 474. France Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 475. France Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 476. France Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 477. France Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 478. Italy Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 479. Italy Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 480. Italy Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 481. Italy Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 482. United Kingdom Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 483. United Kingdom Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 484. United Kingdom Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 485. United Kingdom Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 486. Netherlands Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 487. Netherlands Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 488. Netherlands Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 489. Netherlands Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 490. Rest of Europe Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 491. Rest of Europe Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 492. Rest of Europe Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 493. Rest of Europe Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 494. MEA Anti-Neprilysin Sales, by Country K Tons (2021-2026)
  • Table 495. MEA Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 496. MEA Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 497. MEA Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 498. MEA Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 499. Middle East Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 500. Middle East Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 501. Middle East Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 502. Middle East Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 503. Africa Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 504. Africa Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 505. Africa Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 506. Africa Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 507. North America Anti-Neprilysin Sales, by Country K Tons (2021-2026)
  • Table 508. North America Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 509. North America Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 510. North America Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 511. North America Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 512. United States Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 513. United States Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 514. United States Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 515. United States Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 516. Canada Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 517. Canada Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 518. Canada Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 519. Canada Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 520. Mexico Anti-Neprilysin Sales, by Type K Tons (2021-2026)
  • Table 521. Mexico Anti-Neprilysin Sales, by Application K Tons (2021-2026)
  • Table 522. Mexico Anti-Neprilysin Sales, by Distribution Channel K Tons (2021-2026)
  • Table 523. Mexico Anti-Neprilysin Sales, by End-Use K Tons (2021-2026)
  • Table 524. Anti-Neprilysin: by Type(USD/Units)
  • Table 525. Research Programs/Design for This Report
  • Table 526. Key Data Information from Secondary Sources
  • Table 527. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-Neprilysin: by Type USD Million (2015-2020)
  • Figure 5. Global Anti-Neprilysin: by Application USD Million (2015-2020)
  • Figure 6. Global Anti-Neprilysin: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Anti-Neprilysin: by End-Use USD Million (2015-2020)
  • Figure 8. South America Anti-Neprilysin Share (%), by Country
  • Figure 9. Asia Pacific Anti-Neprilysin Share (%), by Country
  • Figure 10. Europe Anti-Neprilysin Share (%), by Country
  • Figure 11. MEA Anti-Neprilysin Share (%), by Country
  • Figure 12. North America Anti-Neprilysin Share (%), by Country
  • Figure 13. Global Anti-Neprilysin: by Type K Tons (2015-2020)
  • Figure 14. Global Anti-Neprilysin: by Application K Tons (2015-2020)
  • Figure 15. Global Anti-Neprilysin: by Distribution Channel K Tons (2015-2020)
  • Figure 16. Global Anti-Neprilysin: by End-Use K Tons (2015-2020)
  • Figure 17. South America Anti-Neprilysin Share (%), by Country
  • Figure 18. Asia Pacific Anti-Neprilysin Share (%), by Country
  • Figure 19. Europe Anti-Neprilysin Share (%), by Country
  • Figure 20. MEA Anti-Neprilysin Share (%), by Country
  • Figure 21. North America Anti-Neprilysin Share (%), by Country
  • Figure 22. Global Anti-Neprilysin: by Type USD/Units (2015-2020)
  • Figure 23. Global Anti-Neprilysin share by Players 2020 (%)
  • Figure 24. Global Anti-Neprilysin share by Players (Top 3) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Bioprojet SCR (France) Revenue, Net Income and Gross profit
  • Figure 27. Bioprojet SCR (France) Revenue: by Geography 2020
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Pharmaleads SA (France) Revenue, Net Income and Gross profit
  • Figure 31. Pharmaleads SA (France) Revenue: by Geography 2020
  • Figure 32. Theravance Biopharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Theravance Biopharma Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 36. Oceanic Pharmachem Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 37. Oceanic Pharmachem Pvt. Ltd. (India) Revenue: by Geography 2020
  • Figure 38. Global Anti-Neprilysin: by Type USD Million (2021-2026)
  • Figure 39. Global Anti-Neprilysin: by Application USD Million (2021-2026)
  • Figure 40. Global Anti-Neprilysin: by Distribution Channel USD Million (2021-2026)
  • Figure 41. Global Anti-Neprilysin: by End-Use USD Million (2021-2026)
  • Figure 42. South America Anti-Neprilysin Share (%), by Country
  • Figure 43. Asia Pacific Anti-Neprilysin Share (%), by Country
  • Figure 44. Europe Anti-Neprilysin Share (%), by Country
  • Figure 45. MEA Anti-Neprilysin Share (%), by Country
  • Figure 46. North America Anti-Neprilysin Share (%), by Country
  • Figure 47. Global Anti-Neprilysin: by Type K Tons (2021-2026)
  • Figure 48. Global Anti-Neprilysin: by Application K Tons (2021-2026)
  • Figure 49. Global Anti-Neprilysin: by Distribution Channel K Tons (2021-2026)
  • Figure 50. Global Anti-Neprilysin: by End-Use K Tons (2021-2026)
  • Figure 51. South America Anti-Neprilysin Share (%), by Country
  • Figure 52. Asia Pacific Anti-Neprilysin Share (%), by Country
  • Figure 53. Europe Anti-Neprilysin Share (%), by Country
  • Figure 54. MEA Anti-Neprilysin Share (%), by Country
  • Figure 55. North America Anti-Neprilysin Share (%), by Country
  • Figure 56. Global Anti-Neprilysin: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Bioprojet SCR (France)
  • Novartis AG (Switzerland)
  • Pharmaleads SA (France)
  • Theravance Biopharma Inc. (United States)
  • Cipla Limited (India)
  • Oceanic Pharmachem Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Jul 2021 230 Pages 81 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-Neprilysin Market Quantitative research analysis
Global Anti-Neprilysin Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Anti-Neprilysin market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Anti-Neprilysin market are Bioprojet SCR (France), Novartis AG (Switzerland), Pharmaleads SA (France), Theravance Biopharma Inc. (United States), Cipla Limited (India) and Oceanic Pharmachem Pvt. Ltd. (India), to name a few.
In this highly competitive & fast evolving Anti-Neprilysin industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Anti-Neprilysin Market Report?

Have a Query? Click Here

Other Related Reports

Cholesterol Lowering Agents Comprehensive Study by Type (Statins and Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, Others), Application (Hospital...
$ 3750
Acyclovir Injection Comprehensive Study by Type (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others), Application (HIV, Hepatitis, Herpes Simplex Virus, I...
$ 3750
Liposome Assisted Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others), Application (Fungal Infection Therapy, Cancer and Tumor Th...
$ 3750
Heart Disease Drugs Comprehensive Study by Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), Disease (Hypertension, Hyperlipidemia, Coronary Artery Disease...
$ 3650
Cholesterol Drug Comprehensive Study by Type (Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin, Pitavastatin (Livalo), Pravastatin (Pravachol), Rosuvastatin calcium (Crestor), Simvastatin (Zo...
$ 3750
Smart Pill Dispenser Comprehensive Study by Type (Centralized automated dispensing system (Robots and Carousels), Decentralized automated dispensing system (Pharmacy-based automated dispensing system...
$ 3650